2021
DOI: 10.1007/s11605-021-04993-4
|View full text |Cite
|
Sign up to set email alerts
|

The Discordance of Clinical and Pathologic Staging in Locally Advanced Gastric Adenocarcinoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

1
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 13 publications
(4 citation statements)
references
References 30 publications
1
3
0
Order By: Relevance
“…First, the NCDB does not provide any information about the specific clinical staging modalities used in each patient's management. Despite this, we report staging concordance rates that are compatible with previous reports on clinical staging performance, which support the validity of our methods and findings 21,25 . Second, we opted to include staging concordance data from patients who received NAT, among whom treatment response would have misclassified the true disease stage because of clinical staging inaccuracy and treatment down‐staging.…”
Section: Discussionsupporting
confidence: 83%
See 2 more Smart Citations
“…First, the NCDB does not provide any information about the specific clinical staging modalities used in each patient's management. Despite this, we report staging concordance rates that are compatible with previous reports on clinical staging performance, which support the validity of our methods and findings 21,25 . Second, we opted to include staging concordance data from patients who received NAT, among whom treatment response would have misclassified the true disease stage because of clinical staging inaccuracy and treatment down‐staging.…”
Section: Discussionsupporting
confidence: 83%
“…One potential strategy to mitigate the inherent inaccuracy of current clinical staging in GC patients would be identifying those at highest risk for under‐staging. For example, recent data suggest younger age, poor or undifferentiated tumor grade, and days from diagnosis to surgery are predictors of clinical under‐staging 25 . Accounting for clinical staging inaccuracy among GC patients by offering NAT to those with less advanced disease but who are believed to be at high risk of under‐staging would guarantee that a higher proportion of patients receive the benefits of NAT.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…2 b)) had an independent and clinically meaningful impact on PFS in our cohort. Due to the considerable discordance between clinical and pathologic staging of resectable, locally advanced gastric cancer (Papageorge et al 2021 ), cT stage and cN stage were excluded from the backward stepwise covariable selection procedure for PFS multivariable analysis in Model 2 (Fig. 2 b).…”
Section: Discussionmentioning
confidence: 99%